Swedish Orphan Biovitrum AB’s (publ) (Sobi™) CEO Geoffrey McDonough has divested
300,000 of the shares he holds in the company. The sale was made for personal
financial reasons. After the transaction, the CEO will hold a total of 347,948
shares in the company.
---
About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products across Europe, the Middle
East, North Africa and Russia for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO: SOBI) is listed on
Nasdaq Stockholm.
For more information please contact
Media relations Investor relations
Charlotte af Klercker, Sr Jörgen Winroth, Vice
Communications Manager President, Head of Investor
Relations
T: +46-707-297 327 T: +1 347-224-0819, +1 212
-579-0506, +46 8 697 2135
charlotte.afklercker@sobi.com jorgen.winroth@sobi.com
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00 www.sobi.com
